Winter Virtual Symposium

Endocrine Therapy for Gynecologic and Other Cancers: Many Targets, Many Indications

Thursday, Feb 10, 2022 - 10:00 am - 2 pm (EST)
NRG Oncology Winter 2022 Meeting #NRG2022

Program Co-Chairs

Gini Fleming, MD
University Of Chicago

Stéphanie Gaillard, MD, PhD
Johns Hopkins School of Medicine

Shannon Westin, MD, MPH
UT MD Anderson Cancer Center

Speakers/Moderators

Aditya Bardia, MD, MPH
Mass General Hospital

Suzanne Conzen, MD
UT Southwestern Med Ctr

Bradley Corr, MD
Univ of Colorado Sch of Med

Linda Duska, MD, MPH
UVA School of Med

Amanda Nickles Fader, MD
Johns Hopkins Medicine

David Gershenson, MD
UT MD Anderson Can Ctr

Gregory Gressel, MD
Spectrum Health Can Ctr

Marilyn Huang, MD, MS
Univ of Miami Sch of Med

Katherine Kurnit, MD, MPH
Univ of Chicago Medicine

Joyce Liu, MD, MPH
DFCI Harvard Med Sch

Helen Mackay, MD
Sunnybrook Health Sciences Ctr

Michaela Onstad Grinsfelder, MD
MD Anderson Can Ctr

Rebecca Previs, MD
Duke Univ Med Ctr

Russell Szumlewitz, MD
Univ of Chicago Medicine
Winter Symposium Agenda (Virtual Session)

**Endocrine Therapy for Gynecologic and Other Cancers: Many Targets, Many Indications**

**Thursday, February 10, 2022 – 10 am to 2 pm - EST**

**NRG Oncology Winter 2022 Virtual Meeting**

Program Co-Chairs: Gini Fleming, MD, Stephanie Gaillard, MD, PHD, Shannon N. Westin, MD, MPH

**PROGRAM DESCRIPTION:**

The Winter 2022 Virtual Educational Symposium is titled *Endocrine Therapy for Gynecologic and Other Cancers: Many Targets, Many Indications* with noted Oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, Patient Advocates and others engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, Physician Assistants, and other interested Allied Health professionals.

The speakers will focus their presentations on 1) appropriate settings to utilize currently available endocrine therapies, 2) current clinical trials of novel endocrine therapies, and 3) promising future approaches in endocrine therapy.

**LEARNING OBJECTIVES:**

Following this activity, participants will be better able to:

- Recognize appropriate settings to utilize currently available endocrine therapies
- Identify appropriate clinical trial opportunities for patients
- Distinguish promising future approaches

<table>
<thead>
<tr>
<th>Time (MST)</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Welcome/Open Remarks</td>
<td>Gini Fleming, MD</td>
</tr>
<tr>
<td><strong>8:10 am</strong></td>
<td><strong>Session 1 – Current Approaches</strong></td>
<td><strong>Moderator: Bradley Corr, MD (GOG New Investigator)</strong></td>
</tr>
<tr>
<td>8:10-8:20</td>
<td>Basics of Endocrine Therapy</td>
<td>Stéphanie Gaillard, MD, PhD</td>
</tr>
<tr>
<td>8:20-8:40</td>
<td>Overview of Endocrine Therapy in GYN Cancers</td>
<td>Helen MacKay, MD</td>
</tr>
<tr>
<td>8:40-9:00</td>
<td>Debate: AI vs Chemo/AI for LGSOC</td>
<td>Amanda Nickles Fader, MD &amp; David Gershenson, MD</td>
</tr>
<tr>
<td>9:00-9:10</td>
<td>Panel Q &amp; A</td>
<td></td>
</tr>
<tr>
<td><strong>9:10-9:20</strong></td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td><strong>9:20</strong></td>
<td><strong>Session 2 – Overcoming Resistance to Endocrine Therapy</strong></td>
<td><strong>Moderator: Rebecca Previs, MD (GOG New Investigator)</strong></td>
</tr>
<tr>
<td>9:20-9:40</td>
<td>Lessons from Breast Cancer Therapy</td>
<td>Aditya Bardia, MD, MPH</td>
</tr>
<tr>
<td>9:40-9:55</td>
<td>CDK4/6 Inhibitors</td>
<td>Marilyn Huang, MD, MS (GOG New Investigator)</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>9:55-10:10</td>
<td>PI3K Inhibitors</td>
<td>Michaela Onstad Grinsfelder, MD, MPH</td>
</tr>
<tr>
<td>10:10-10:25</td>
<td>Epigenetic therapies</td>
<td>Linda Duska, MD</td>
</tr>
<tr>
<td>10:25-10:35</td>
<td>Panel Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>10:35-10:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Session 3 – New Directions</td>
<td>Moderator: Gregory Gessel, MD (GOG New Investigator)</td>
</tr>
<tr>
<td>10:45-11:05</td>
<td>Androgen Approaches in Prostate Cancer</td>
<td>Russell Szmulewitz, MD</td>
</tr>
<tr>
<td>11:05-11:15</td>
<td>Androgen Receptors Therapy for Gynecologic Cancers</td>
<td>Katherine Kurnit, MD (GOG New Investigator)</td>
</tr>
<tr>
<td>11:15-11:35</td>
<td>Glucocorticoid Receptors</td>
<td>Suzanne Conzen, MD</td>
</tr>
<tr>
<td>11:35-11:50</td>
<td>Organoids as Model Systems</td>
<td>Joyce Liu, MD, MPH</td>
</tr>
<tr>
<td>11:50-12:00</td>
<td>Panel Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>12:00-12:05</td>
<td>Closing Remarks</td>
<td>Shannon Westin, MD</td>
</tr>
</tbody>
</table>

Continuing Education

Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this on demand activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants who complete the educational activity and evaluation will receive a certificate of credit.

Registration
Registration and other meeting information is available on the NRG website:
To register visit: https://www.nrgoncology.org/NRG2022-Winter-Meeting/Registration (Registration coming soon)
Symposium Registration Fee: $150

Disclosure Declaration
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. All relevant financial relationships listed for these individuals have been mitigated to ensure a bias-free presentation. Please see the faculty disclosure list for detailed information.